BioLife Solutions, Inc.
BLFS
Positions held
Your positionsBLFS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- BioLife Solutions operates in the growing medical instruments and supplies industry, which is expected to see increased demand due to advancements in healthcare technology and an aging population.
- The company's revenue grew by 21.5% year-over-year, reaching $68.016 million in 2023.
- In the latest quarter, BioLife reported a gross margin of 64.2%, an improvement from 63.6% in the prior quarter.
- The company has a high debt-to-equity ratio of 3.747, indicating potential financial risk.
- BioLife Solutions reported a net income loss of $68.002 million in 2023, reflecting ongoing profitability challenges.
- The operating margin was negative at -28.5% for the year 2023, highlighting operational inefficiencies.
Fundamentals
| Market cap | $1.89B | Enterprise value | $1.82B | Trailing P/E | 39.00 | Forward P/E | 117.00 |
| PEG | 15.09 | Price / book | 4.49 | Beta | 1.82 | Dividend yield | 0.00% |
| Revenue growth | 21.5% | Earnings growth | — | Gross margin | 63.6% | Operating margin | 6.0% |
| Profit margin | 54.3% | ROE | 12.8% | ROA | 0.3% | Debt / equity | 0.04 |
| Current ratio | 9.69 | Free cash flow | $4.66M | Analyst recommendation | hold | Mean target | $31.00 |
| 52w high | $39.76 | 52w low | $17.86 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $28.5M | $27.5M | $18.8M | $28.1M | $23.4M | — |
| Op margin | 6.0% | 0.1% | 7.2% | -0.3% | -68.8% | — |
| Net income | $45.1M | $1.2M | $11.1M | $0.6M | -$15.8M | — |
| Gross margin | 64.2% | 63.6% | 63.8% | 63.9% | 65.0% | — |
| Gross profit | $18.3M | $17.5M | $12.0M | $17.9M | $15.2M | — |
| Operating income | $1.7M | $0.0M | $1.3M | -$0.1M | -$16.1M | — |
- Revenue +4% vs prior quarter ($28M vs $28M).
- Gross margin 64.2% (was 63.6% prior quarter).
- Operating margin expanded to 6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $96.2M | $74.6M | $68.0M | $76.2M | — |
| Op margin | -17.3% | -6.0% | -28.5% | -14.0% | — |
| Net income | -$4.6M | -$20.2M | -$68.0M | -$140M | — |
| Gross margin | 64.6% | 67.1% | 60.7% | 61.5% | — |
| Gross profit | $62.1M | $50.1M | $41.3M | $46.9M | — |
| Operating income | -$16.6M | -$4.5M | -$19.4M | -$10.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Why Freshworks Stock Bumped Higher Today
2026-10-06 · Why Are Freshworks (FRSH) Shares Soaring Today
2026-10-06 · Repligen Closes BioLife Solutions Acquisition
2026-10-06 · Repligen Completes Acquisition of BioLife Solutions
2026-10-05 · Freshworks Set to Join S&P SmallCap 600
2026-10-05 · Freshworks stock climbs on S&P SmallCap 600 inclusion
2026-10-05 · Freshworks to Join S&P SmallCap 600
2026-10-05 · BioLife Solutions Shareholders Approve Repligen Merger Agreement
2026-09-24 · This Long-Term Winning Stock Is in a Growth Market and Just Hit New 3-Year Highs
2026-09-04 · Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching Cost
2026-08-07 · BioLife Solutions (BLFS) Is Up 7.2% After Swinging From Loss To Q2 Profit - What's Changed
2026-08-06 · BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates
Price (daily)
Full chart · RSI · MACD · patterns